Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Tecovirimat is an antiviral medication used to treat smallpox, monkeypox, and cowpox. The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.
- Mechanism
- Curator reviewed · 10 references
Successful viral replication leads to the formation of a number of infectious virion forms. Mature viruses are infectious but remain intracellularly until cell lysis. On the other hand, enveloped virion form is created when mature viruses wrap with late endosomal membranes. The formation of a wrapping complex for enveloped virions is mediated by the orthopoxvirus P37 protein. These egress-competent enveloped virions are released in a nonlytic fashion from the cell and play an essential role in cell-to-cell and long-range dissemination of the virus in the host.
The P37 protein is encoded by a highly conserved gene in all members of the orthopoxvirus genus. P37 interacts with the Rab9 GTPase and TIP47, which are components of late endosome-derived transport vesicles. Interaction of P37 and Rab9 GTPase and TIP47 leads to the formation of the virus-specific wrapping complex for enveloped virions. Tecovirimat is an inhibitor of P37: it blocks the interaction of P37 with Rab9 and TIP47, preventing the formation of the wrapping complex.
- Primary indication
- Tecovirimat is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.Curator reviewed · 5 structured indications
- Formula / weight
- C19H15F3N2O3 · 376.335 g/mol (avg)
- First approval
- Canada, 2021 · United States, 2018 · European Union, 2022
- Code names
- SIGA-246 · ST-246
- Brand names
- Tecovirimat Siga
- Tpoxx
Resolves to
CSKDFZIMJXRJGH-VWLPUNTISA-NSMILESFC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Tecovirimat, and which of those have an active Phase 3 trial?